Molecular Imaging of Intracellular Drug-Membrane Aggregate Formation

被引:54
作者
Baik, Jason [1 ]
Rosania, Gus R. [1 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
关键词
drug sequestration; autophagosome-like drug inclusion; drug-membrane aggregates; clofazimine; confocal Raman imaging; phospholipidosis; intracellular crystals; INDUCED PHOSPHOLIPIDOSIS; CLOFAZIMINE; ACCUMULATION; AUTOPHAGY; PHARMACOLOGY; AMIODARONE; BINDING; EGRESS;
D O I
10.1021/mp200101b
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Clofazimine is a lipophilic antibiotic with an extremely long pharmacokinetic half-life associated with the appearance of crystal-like drug inclusions, in vivo. Here, we studied how clofazimine accumulates inside cells in the presence of supersaturating, extracellular concentrations of the drug (in the range of physiological drug concentrations). Based on a combination of molecular imaging, biochemical analysis and electron microscopy techniques, clofazimine mass increased inside cells in vitro, over a period of several days, with discrete clofazimine inclusions forming in the cytoplasm. These inclusions grew in size, number and density, as long as the drug-containing medium was replenished. With Raman confocal microscopy, clofazimine's spectral signature in these inclusions resembled that of amorphous clofazimine precipitates and was unlike that of clofazimine crystals. Additional experiments revealed that clofazimine first accumulated in mitochondria, with ensuing changes in mitochondrial structure and function. In turn, the degenerating organelles coalesced, fused with each other and condensed to form prominent drug-membrane aggregates (dubbed autophagosome-like drug inclusions or "aldis"). Like clofazimine, it is possible that intracellular drug-membrane aggregate formation is a common phenomenon underlying the reported phenotypic effects of many other small molecule drugs.
引用
收藏
页码:1742 / 1749
页数:8
相关论文
共 35 条
[1]
Screening for the Drug-Phospholipid Interaction: Correlation to Phospholipidosis [J].
Alakoskela, Juha-Matti ;
Vitovic, Pavol ;
Kinnunen, Paavo K. J. .
CHEMMEDCHEM, 2009, 4 (08) :1224-1251
[2]
Atkinson A J Jr, 1967, Int J Lepr Other Mycobact Dis, V35, P119
[3]
Subcellular pharmacokinetics and its potential for library focusing [J].
Balaz, S ;
Lukacova, V .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2002, 20 (06) :479-490
[4]
Modeling Kinetics of Subcellular Disposition of Chemicals [J].
Balaz, Stefan .
CHEMICAL REVIEWS, 2009, 109 (05) :1793-1899
[5]
SOME OBSERVATIONS ON PHARMACOLOGY OF CLOFAZIMINE (B663) [J].
BANERJEE, DK ;
ELLARD, GA ;
GAMMON, PT ;
WATERS, MFR .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1974, 23 (06) :1110-1115
[6]
BARTLETT GR, 1959, J BIOL CHEM, V234, P466
[7]
The role of the VPS4a-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug [J].
Chen, Vivien Y. ;
Posada, Maria M. ;
Blazer, Levi L. ;
Zhao, Tong ;
Rosania, Gus R. .
PHARMACEUTICAL RESEARCH, 2006, 23 (08) :1687-1695
[8]
Label-Free Raman Spectral Imaging of Intracellular Delivery and Degradation of Polymeric Nanoparticle Systems [J].
Chernenko, Tatyana ;
Matthaeus, Christian ;
Milane, Lara ;
Quintero, Luis ;
Amiji, Mansoor ;
Diem, Max .
ACS NANO, 2009, 3 (11) :3552-3559
[9]
CONALTY M L, 1971, International Journal of Leprosy and Other Mycobacterial Diseases, V39, P479
[10]
LYSOSOMOTROPIC AGENTS [J].
DEDUVE, C ;
DEBARSY, T ;
POOLE, B ;
TROUET, A ;
TULKENS, P ;
VANHOOF, F .
BIOCHEMICAL PHARMACOLOGY, 1974, 23 (18) :2495-+